0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes

      Therapeutics and Clinical Risk Management

      Dove Medical Press

      saxagliptin, incretins, type 2 diabetes, DPP-4 inhibitors

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Type 2 diabetes is associated with decreased incretin hormone response to an oral glucose load, and a progressive decline in postprandial glucagon-like peptide-1 (GLP-1) secretion. Incretin-based therapies offer a new option for treatment of type 2 diabetes. Saxagliptin, a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor specifically designed for extended inhibition of the DPP-4 enzyme, causes increased endogenous GLP-1 concentration. In a phase 3 clinical trials program of 24 weeks duration, saxagliptin was studied in 6 multicenter, multinational, randomized, controlled studies and in combination with 3 of the most commonly administered oral antidiabetic drugs: metformin, glyburide and a thiozolidinedione (TZD). Saxagliptin provided significant reductions in hemoglobin HbA 1c when given with metformin, glyburide, a TZD, or as monotherapy. Saxagliptin also reduced fasting plasma glucose and 2-hour post-prandial glucose in each of these studies, and was weight and lipid neutral. Saxagliptin was well tolerated and had a low risk of hypoglycemia when used as monotherapy.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2010
          2010
          25 May 2010
          : 6
          : 233-237
          Affiliations
          Baylor College of Medicine, Houston, Texas, USA
          Author notes
          Correspondence: Morali D Sharma, Associate Professor of Medicine, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, 1709 Dryden, Suite 1000, Houston, TX 77030, USA, Tel +1 (713) 798-4736, Fax +1 (713) 798-4593, Email msharma@ 123456bcm.edu
          Article
          tcrm-6-233
          2878957
          20526441
          © 2010 Sharma, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          saxagliptin, incretins, type 2 diabetes, dpp-4 inhibitors

          Comments

          Comment on this article